Vitamin D Depletion: Medications, Symptoms & Food Sources

Vitamin D is technically a hormone, not a vitamin — it regulates over 1,000 genes across virtually every tissue in your body. Its most recognized role is controlling intestinal calcium absorption (boosting it from 10-15% to 30-40%), but its influence extends far beyond bones. Vitamin D modulates both innate and adaptive immune function, supports antimicrobial peptide production (cathelicidin and defensins), regulates inflammatory cytokines, influences serotonin production in the brain, and plays a role in insulin sensitivity and blood pressure regulation. Your skin produces vitamin D3 when UVB radiation converts 7-dehydrocholesterol to cholecalciferol, but this process requires direct sun exposure at specific angles — above latitude 35 degrees north, UVB intensity is insufficient for vitamin D synthesis during winter months. The CTD database catalogs 74 randomized controlled trials involving vitamin D across 799,488 patients, with PubMed indexing 8,526 articles and 167 meta-analyses covering bone health, immune function, mood disorders, and cancer risk reduction.

Vitamin D activation requires a two-step conversion process that makes it uniquely vulnerable to depletion. First, the liver converts cholecalciferol to 25-hydroxyvitamin D (calcidiol) via the CYP2R1 enzyme. Then the kidneys convert calcidiol to 1,25-dihydroxyvitamin D (calcitriol, the active hormone) via CYP27B1. Both conversion steps require magnesium as a cofactor — without adequate magnesium, vitamin D supplementation is literally ineffective because the vitamin cannot be activated regardless of dose. This dual-enzyme pathway creates multiple points where medications can interfere: anticonvulsants induce CYP enzymes that accelerate vitamin D catabolism, corticosteroids alter receptor sensitivity and metabolism, and the resulting depletion cascades into calcium malabsorption, immune dysfunction, and mood disturbance. An estimated 42% of US adults are vitamin D deficient (below 30 ng/mL), with rates climbing to over 80% in dark-skinned populations and those living at northern latitudes.

The anticonvulsant-plus-corticosteroid combination is one of the most devastating vitamin D double depletion patterns in clinical medicine. Anticonvulsants induce CYP enzymes that destroy vitamin D at an accelerated rate, while corticosteroids simultaneously reduce vitamin D receptor expression, impair kidney activation, and accelerate catabolism through a separate pathway. Together, they create a state of severe vitamin D insufficiency that causes osteomalacia (softened bones that bend and fracture), increased fall risk from proximal muscle weakness, and impaired immune function. This combination is disturbingly common in neurological patients with epilepsy who require corticosteroids for related inflammatory conditions. These patients need 5,000-10,000 IU of D3 daily with quarterly 25-OH-D monitoring, calcium citrate supplementation, and bone density screening.

The anticonvulsant-plus-magnesium-depleting-drug pattern creates a secondary vitamin D depletion cascade through cofactor depletion. Anticonvulsants destroy vitamin D directly, and if the patient is simultaneously on a PPI or thiazide diuretic that depletes magnesium, the remaining vitamin D cannot be activated because both conversion enzymes (CYP2R1 and CYP27B1) require magnesium as a cofactor. This creates a situation where even aggressive vitamin D supplementation fails because the activation machinery is disabled by magnesium depletion. The patient tests low on 25-OH-D, receives a vitamin D prescription, retests months later and is still low — and nobody checks magnesium. Addressing magnesium status is the essential first step before vitamin D repletion in any patient on multiple depleting medications.